TrialJournal of interventional cardiology2013
Would tirofiban have been shown non-inferior to abciximab had the TENACITY trial not been terminated for financial reasons?
Peter B Berger et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.